-
Bristol Myers Squibb announces acquisition of schizophrenia drug manufacturer Karuna for $14 billion
On December 22nd local time, Bristol Myers Squibb and Karuna Therapeutics announced that they had signed a final merger agreement. According to the agreement, Bristol Myers Squibb has agreed to acqui ... -
Johnson&Johnson Long acting Schizophrenic Therapy Approved in China
Johnson&Johnson's long-acting schizophrenia therapy has been approved in China. Johnson&Johnson announced that its long-acting injection, Shanjiuda, which is administered every six months, has recent ... -
Zaiding Medicine: Clinical study of KarXT for the treatment of schizophrenia completed, enrolled patients from mainland China
On August 13th, Zaiding Pharmaceutical announced that the UNITE-1 study of KarXT (Xanomeline Tropium) for schizophrenia has completed the enrollment of all mainland Chinese patients. Zaiding Pharmace ...